About $18 million of tariff reimbursements landed in Gentex's books during the three months ended June 30. That reimbursement helped turn a 1.0% revenue decline into a 7.0% increase in gross profit.
The headline numbers look unusually clean: gross margin rose to 37.0% from 34.2%, operating income climbed 19.3% to $141.3 million, and net income increased 19.4% to $114.7 million. Diluted EPS rose 25.6%, helped by a 5.0% decline in diluted shares.
The margin improvement was not just a tariff story. Gentex also cited favorable product mix, though commodity price increases and lower overall sales pushed the other way. The reimbursement matters because $18 million is roughly 2.8% of quarterly revenue, nearly the entire year-over-year gross-margin expansion when expressed against sales.
Management described the source directly:
"The quarter over quarter increase in the gross margin resulted primarily from approximately $18 million of IEEPA tariff reimbursements received during the quarter, that reduced cost of goods sold as well as favorable product mix, which was partially offset by commodity price increases and the reduction in overall sales levels compared to the second quarter of last year."
Gentex 10-Q, filed Aug. 4, 2026
In plain English, Gentex sold slightly less and kept more of each dollar, but one of the biggest margin supports came from a reimbursement rather than a new sale.
The revenue weakness was not evenly distributed. Gentex said lower sales into China and lower European sales, tied to vehicle mix and certain customer-specific product challenges, weighed on the six months ended June 30. The company did not quantify how much of the three-month decline came from each issue.
Its wording was blunt:
"Sales during the six months ended June 30, 2026, were negatively impacted by lower sales into the China market, as well as lower sales in Europe due to vehicle mix and certain customer-specific product challenges."
Gentex 10-Q, filed Aug. 4, 2026
That gives the profit jump a narrower shape. The business generated more operating income from a smaller sales base, with help from mix, lower engineering-related professional fees, and the tariff reimbursement. Research and development spending fell 4.3% to $49.3 million, with the company citing lower engineering-related professional fees. Separately, the company attributed a quarter-over-quarter decrease to prior-year severance costs.
The balance sheet adds another unresolved detail. Inventory rose 9.1% to $519.0 million, faster than revenue, while accounts receivable increased 3.6%. Cash nearly doubled to $233.4 million, but the six-month cash-flow disclosure attributed the increase in operating cash flow primarily to working-capital changes, including higher accounts payable and accrued liabilities. Capex fell 46.6%, which also supported cash generation.
Gentex's annual history puts the latest period in context without settling the question. Revenue reached $2.5 billion in 2025, up 9.6%, but operating margin declined to 18.7% from 19.9% in 2024. The latest three months show margins moving in the opposite direction, even as sales stopped growing.
At the latest close, Gentex was valued at 13.3 times earnings, with a $5.1 billion market capitalization. That leaves the central accounting question intact rather than answering it: the next three-month report must show what gross margin and inventory look like without another disclosed reimbursement doing part of the work.
Source: Gentex Corporation 10-Q filed Aug. 4, 2026, for the three months ended June 30, 2026.